MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
19.97
-1.71
-7.89%
After Hours: 20.01 +0.04 +0.20% 16:47 03/27 EDT
OPEN
21.67
PREV CLOSE
21.68
HIGH
21.67
LOW
19.72
VOLUME
4.61M
TURNOVER
--
52 WEEK HIGH
76.67
52 WEEK LOW
10.42
MARKET CAP
2.10B
P/E (TTM)
-2.8026
1D
5D
1M
3M
1Y
5Y
1D
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
Benzinga · 3h ago
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
NASDAQ · 5h ago
Could Sarepta Therapeutics’ (SRPT) New siRNA Data Mark a Turning Point Beyond Duchenne Therapies?
Simply Wall St · 13h ago
Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade)
Seeking Alpha · 1d ago
SRPT Stock Surges on Promising Early Results From siRNA Programs
NASDAQ · 1d ago
Sarepta Therapeutics: It's Too Early To Get Excited About siRNA Data
Seeking Alpha · 1d ago
Sarepta Therapeutics Price Target Raised to $13.00/Share From $9.00 by Citigroup
Dow Jones · 1d ago
Sarepta Therapeutics Is Maintained at Sell by Citigroup
Dow Jones · 1d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.